Xeris Biopharma Holdings (XERS) EPS (Diluted) Growth (1y) (2022 - 2026)
Xeris Biopharma Holdings (XERS) EPS (Diluted) Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.64 Bn | 87.78 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | 65.33% |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | 5.88% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -394.16% |
| 5 | United Therapeutics | 22.98 Bn | 20.83 Bn | 648.10 Mn | -12.15% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn | 105.88% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | 2,383.26% |
| 9 | Elanco Animal Health | 12.67 Bn | 12.24 Bn | 785.00 Mn | -16.09% |
| 10 | Xeris Biopharma Holdings | 1.42 Bn | 1.31 Bn | 72.55 Mn | 120.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 120.79% |
| Dec 31, 2025 | 284.14% |
| Sep 30, 2025 | 103.31% |
| Jun 30, 2025 | 88.05% |
| Mar 31, 2025 | 55.22% |
| Dec 31, 2024 | 64.18% |
| Sep 30, 2024 | -19.64% |
| Jun 30, 2024 | 29.99% |
| Mar 31, 2024 | -10.04% |
| Dec 31, 2023 | -2.02% |
| Sep 30, 2023 | 45.02% |
| Jun 30, 2023 | 25.22% |
| Mar 31, 2023 | 50.84% |
| Dec 31, 2022 | 85.17% |
| Sep 30, 2022 | 58.94% |
| Jun 30, 2022 | 53.40% |
| Mar 31, 2022 | 16.94% |